The Europe sarcopenia treatment market is expected to reach USD 1,033,968.39 thousand by 2030 from USD 725,593.95 thousand in 2022, growing at a CAGR of 4.6% in the forecast period of 2023 to 2030 Market Segmentation Europe Sarcopenia Treatment Market, By Treatment Type (Medications, Vitamin/Dietary Supplements, and Others), Type (Primary Sarcopenia and Secondary Sarcopenia), Stages (Pre-Sarcopenia, Sarcopenia, and Severe Sarcopenia), Route Of Administration (Oral, Injectable, and Others), Gender (Male and Female), End User (Hospitals, Specialty Clinics, Home Healthcare, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others), Country (Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, Denmark, Norway, Sweden, Poland, Finland, And Rest Of Europe) - Industry Trends and Forecast to 2030 Overview of Europe Sarcopenia Treatment Market Dynamics: Driver • Rising prevalence of sarcopenia Restraint • Lack of standardized diagnosis Opportunity • Strategic initiatives by key market players Market Players Some of the key market players operating in the Europe sarcopenia treatment market are listed below: • Abbott, • Nestlé Health Science (A subsidiary of Nestlé S.A.) • Novartis AG • Sanofi • Haleon Group of Companies • BASF SE • DSM • Fermenta Biotech Limited • AstaReal Co., Ltd. • Metagenics • Wellona Pharma • The Vitamin Company India • Healing Pharma India Pvt. Ltd • Others

1 INTRODUCTION 26 1.1 OBJECTIVES OF THE STUDY 26 1.2 MARKET DEFINITION 26 1.3 OVERVIEW OF THE EUROPE SARCOPENIA TREATMENT MARKET 26 1.4 CURRENCY AND PRICING 28 1.5 LIMITATIONS 28 1.6 MARKETS COVERED 28 2 MARKET SEGMENTATION 31 2.1 MARKETS COVERED 31 2.2 GEOGRAPHICAL SCOPE 32 2.3 YEARS CONSIDERED FOR THE STUDY 33 2.4 DBMR TRIPOD DATA VALIDATION MODEL 34 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 37 2.6 MULTIVARIATE MODELLING 38 2.7 TREATMENT TYPE SEGMENT LIFELINE CURVE 38 2.8 MARKET END USER COVERAGE GRID 39 2.9 DBMR MARKET POSITION GRID 40 2.10 VENDOR SHARE ANALYSIS 42 2.11 SECONDARY SOURCES 43 2.12 ASSUMPTIONS 43 3 EXECUTIVE SUMMARY 44 4 PREMIUM INSIGHTS 47 4.1 PESTEL ANALYSIS 48 4.2 PORTER’S FIVE FORCES MODEL 49 4.3 CURRENT STATUS OF EMERGING DRUGS FOR SARCOPENIA TREATMENT 50 5 EUROPE SARCOPENIA TREATMENT MARKET: REGULATIONS 51 5.1 REGULATIONS IN U.S 51 5.2 REGULATIONS IN EUROPE 51 5.3 REGULATIONS IN AUSTRALIA 52 5.4 REGULATIONS IN SOUTH AFRICA 52 6 MARKET OVERVIEW 53 6.1 DRIVERS 55 6.1.1 RISING PREVALENCE OF SARCOPENIA 55 6.1.2 GROWING AWARENESS OF SARCOPENIA AND ITS DETRIMENTAL EFFECTS ON HEALTH 55 6.1.3 LIFESTYLE FACTORS SUCH AS POOR NUTRITION AND SEDENTARY BEHAVIOUR 56 6.2 RESTRAINTS 57 6.2.1 LACK OF STANDARDIZED DIAGNOSIS 57 6.2.2 HIGH COST OF TREATMENT AND INTERVENTIONS 57 6.3 OPPORTUNITIES 58 6.3.1 STRATEGIC INITIATIVES BY MARKET PLAYERS 58 6.3.2 INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES 58 6.4 CHALLENGES 59 6.4.1 COMPLICATIONS ASSOCIATED WITH THE SARCOPENIA TREATMENT 59 6.4.2 STRINGENT GOVERNMENT RULES AND REGULATION FOR PRODUCT APPROVAL 60 7 EUROPE SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE 61 7.1 OVERVIEW 62 7.2 VITAMIN/DIETARY SUPPLEMENTS 65 7.2.1 VITAMIN SUPPLEMENTS 66 7.2.2 PROTEIN SUPPLEMENTS 66 7.2.3 FATTY ACID SUPPLEMENTS 66 7.2.4 CREATINE 66 7.2.5 WHEY PROTEINS 66 7.2.6 L-CARNITINE 66 7.2.7 SOY 66 7.2.8 BETA-ALANINE 66 7.2.9 OSTARINE 66 7.2.10 COLLAGEN PEPTIDES 66 7.2.11 LIGANDROL 67 7.2.12 BRANCH-CHAIN AMINO ACIDS 67 7.2.13 HYDROXYMETHYLBUTYRATE (HMB) 67 7.2.14 MEDIUM CHAIN TRIGLYCERIDES 67 7.2.15 OTHERS 67 7.3 MEDICATIONS 67 7.3.1 OFF LABEL DRUGS 68 7.3.2 EMERGING DRUGS 68 7.3.2.1 ACE INHIBITORS 68 7.3.2.2 APPETITE STIMULANTS 68 7.3.2.3 ORAL ANTIDIABETIC DRUGS 68 7.3.2.4 OTHERS 69 7.4 OTHERS 69 8 EUROPE SARCOPENIA TREATMENT MARKET, BY TYPE 70 8.1 OVERVIEW 71 8.2 PRIMARY SARCOPENIA 74 8.2.1 VITAMIN/DIETARY SUPPLEMENTS 74 8.2.2 MEDICATIONS 74 8.2.3 OTHERS 74 8.3 SECONDARY SARCOPENIA 75 8.3.1 VITAMIN/DIETARY SUPPLEMENTS 75 8.3.2 MEDICATIONS 75 8.3.3 OTHERS 75 9 EUROPE SARCOPENIA TREATMENT MARKET, BY STAGES 76 9.1 OVERVIEW 77 9.2 PRE-SARCOPENIA 80 9.3 SARCOPENIA 80 9.4 SEVERE SARCOPENIA 81 10 EUROPE SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 82 10.1 OVERVIEW 83 10.2 ORAL 86 10.3 INJECTABLES 86 10.4 OTHERS 87 11 EUROPE SARCOPENIA TREATMENT MARKET, BY GENDER 88 11.1 OVERVIEW 89 11.2 MALE 92 11.3 FEMALE 92 12 EUROPE SARCOPENIA TREATMENT MARKET, BY END USER 93 12.1 OVERVIEW 94 12.2 HOSPITALS 97 12.2.1 PUBLIC 97 12.2.2 PRIVATE 97 12.3 SPECIALTY CLINICS 98 12.4 HOME HEALTHCARE 98 12.5 OTHERS 99 13 EUROPE SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL 100 13.1 OVERVIEW 101 13.2 DIRECT TENDER 104 13.3 RETAIL SALES 104 13.3.1 HOSPITAL PHARMACIES 105 13.3.2 ONLINE PHARMACIES 105 13.3.3 OTHERS 105 13.4 OTHERS 105 14 EUROPE SARCOPENIA TREATMENT MARKET, BY REGION 106 14.1 EUROPE 109 14.1.1 GERMANY 116 14.1.2 FRANCE 122 14.1.3 U.K 128 14.1.4 ITALY 134 14.1.5 SPAIN 140 14.1.6 RUSSIA 146 14.1.7 TURKEY 152 14.1.8 BELGIUM 158 14.1.9 NETHERLANDS 164 14.1.10 SWITZERLAND 170 14.1.11 DENMARK 176 14.1.12 NORWAY 182 14.1.13 SWEDEN 188 14.1.14 POLAND 194 14.1.15 FINLAND 201 14.1.16 REST OF EUROPE 207 15 EUROPE SARCOPENIA TREATMENT MARKET, COMPANY LANDSCAPE 208 15.1 COMPANY SHARE ANALYSIS: EUROPE 208 16 SWOT ANALYSIS 209 17 COMPANY PROFILE 210 17.1 ABBOTT 210 17.1.1 COMPANY SNAPSHOT 210 17.1.2 REVENUE ANALYSIS 210 17.1.3 COMPANY SHARE ANALYSIS 211 17.1.4 PRODUCT PORTFOLIO 211 17.1.5 RECENT DEVELOPMENT 211 17.2 NESTLÉ HEALTH SCIENCE (A SUBSIDIARY OF NESTLÉ S.A.) 212 17.2.1 COMPANY SNAPSHOT 212 17.2.2 REVENUE ANALYSIS 212 17.2.3 COMPANY SHARE ANALYSIS 213 17.2.4 PRODUCT PORTFOLIO 213 17.2.5 RECENT DEVELOPMENT 213 17.3 NOVARTIS AG 214 17.3.1 COMPANY SNAPSHOT 214 17.3.2 REVENUE ANALYSIS 214 17.3.3 COMPANY SHARE ANALYSIS 215 17.3.4 PRODUCT PORTFOLIO 215 17.3.5 PIPELINE PORTFOLIO 215 17.3.6 RECENT DEVELOPMENT 215 17.4 SANOFI 216 17.4.1 COMPANY SNAPSHOT 216 17.4.2 REVENUE ANALYSIS 216 17.4.3 COMPANY SHARE ANALYSIS 217 17.4.4 PRODUCT PORTFOLIO 217 17.4.5 RECENT DEVELOPMENT 217 17.5 HALEON GROUP OF COMPANIES 218 17.5.1 COMPANY SNAPSHOT 218 17.5.2 REVENUE ANALYSIS 218 17.5.3 COMPANY SHARE ANALYSIS 219 17.5.4 PRODUCT PORTFOLIO 219 17.5.5 RECENT DEVELOPMENT 219 17.6 ASTAREAL CO., LTD 220 17.6.1 COMPANY SNAPSHOT 220 17.6.2 PRODUCT PORTFOLIO 220 17.6.3 RECENT DEVELOPMENT 220 17.7 BASF SE 221 17.7.1 COMPANY SNAPSHOT 221 17.7.2 REVENUE ANALYSIS 221 17.7.3 PRODUCT PORTFOLIO 222 17.7.4 RECENT DEVELOPMENT 222 17.8 BIOGEN SA 223 17.8.1 COMPANY SNAPSHOT 223 17.8.2 PRODUCT PORTFOLIO 223 17.8.3 RECENT DEVELOPMENT 223 17.9 BIOTHRIVE SCIENCES 224 17.9.1 COMPANY SNAPSHOT 224 17.9.2 PRODUCT PORTFOLIO 224 17.9.3 RECENT DEVELOPMENT 224 17.10 DSM 225 17.10.1 COMPANY SNAPSHOT 225 17.10.2 REVENUE ANALYSIS 225 17.10.3 PRODUCT PORTFOLIO 226 17.10.4 RECENT DEVELOPMENT 226 17.11 FERMENTA BIOTECH LIMITED 227 17.11.1 COMPANY SNAPSHOT 227 17.11.2 REVENUE ANALYSIS 227 17.11.3 PRODUCT PORTFOLIO 228 17.11.4 RECENT DEVELOPMENT 228 17.12 HEALING PHARMA INDIA PVT. LTD 229 17.12.1 COMPANY SNAPSHOT 229 17.12.2 PRODUCT PORTFOLIO 229 17.12.3 RECENT DEVELOPMENT 229 17.13 METAGENICS 230 17.13.1 COMPANY SNAPSHOT 230 17.13.2 PRODUCT PORTFOLIO 230 17.13.3 RECENT DEVELOPMENT 230 17.14 THE VITAMIN COMPANY INDIA 231 17.14.1 COMPANY SNAPSHOT 231 17.14.2 PRODUCT PORTFOLIO 231 17.14.3 RECENT DEVELOPMENT 231 17.15 WELLONA PHARMA 232 17.15.1 COMPANY SNAPSHOT 232 17.15.2 PRODUCT PORTFOLIO 232 17.15.3 RECENT DEVELOPMENT 232 17.16 ARMGO PHARMA, INC 233 17.16.1 COMPANY SNAPSHOT 233 17.16.2 PIPELINE PORTFOLIO 233 17.16.3 RECENT DEVELOPMENT 233 17.17 BIOPHYTIS 234 17.17.1 COMPANY SNAPSHOT 234 17.17.2 PIPELINE PORTFOLIO 234 17.17.3 RECENT DEVELOPMENT 234 17.18 DYSTROGEN THERAPEUTICS CORP 235 17.18.1 COMPANY SNAPSHOT 235 17.18.2 PIPELINE PORTFOLIO 235 17.18.3 RECENT DEVELOPMENT 235 17.19 IMMUNOFORGE INC 236 17.19.1 COMPANY SNAPSHOT 236 17.19.2 PIPELINE PORTFOLIO 236 17.19.3 RECENT DEVELOPMENT 236 17.20 MYMD PHARMACEUTICALS 237 17.20.1 COMPANY SNAPSHOT 237 17.20.2 PIPELINE PORTFOLIO 237 17.20.3 RECENT DEVELOPMENT 237 17.21 NMD PHARMA A/S 238 17.21.1 COMPANY SNAPSHOT 238 17.21.2 PIPELINE PORTFOLIO 238 17.21.3 RECENT DEVELOPMENT 238 17.22 ONCOCROSS CO., LTD 239 17.22.1 COMPANY SNAPSHOT 239 17.22.2 PIPELINE PORTFOLIO 239 17.22.3 RECENT DEVELOPMENT 239 17.23 OPKO HEALTH, INC 240 17.23.1 COMPANY SNAPSHOT 240 17.23.2 REVENUE ANALYSIS 240 17.23.3 PIPELINE PORTFOLIO 241 17.23.4 RECENT DEVELOPMENT 241 17.24 REGENERON PHARMACEUTICALS INC 242 17.24.1 COMPANY SNAPSHOT 242 17.24.2 REVENUE ANALYSIS 242 17.24.3 PIPELINE PORTFOLIO 243 17.24.4 RECENT DEVELOPMENT 243 17.25 REJUVENATE BIOMED NV 244 17.25.1 COMPANY SNAPSHOT 244 17.25.2 PIPELINE PORTFOLIO 244 17.25.3 RECENT DEVELOPMENT 244 18 QUESTIONNAIRE 245 19 RELATED REPORTS 249